Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Raul Santos Articles

Evolocumab in lower extremity peripheral artery disease

Evolocumab in lower extremity peripheral artery disease

Lower extremity peripheral artery disease (LEPAD) is associated with an elevated risk of atherosclerotic cardiovascular disease (ASCVD) and mortality1. Classically, risk factors for LEPAD are heavy smoking, diabetes and older age, although dyslipidaemia also predisposes to LEPAD, as shown by a recent study2. Furthermore, Pereira…

read more »
PlayProf Raul Santos: SPIRE trials with bococizumab

Prof Raul Santos: SPIRE trials with bococizumab

The data from the SPIRE programme, especially SPIRE-1 and SPIRE-2 the cardiovascular outcomes studies was also illuminating. PCSK9 Forum Editor Professor Raul Santos, one of the authors, gives his view.

read more »
Insights from Brazil: Raul Santos, InCor-University of Sao Paulo

Insights from Brazil: Raul Santos, InCor-University of Sao Paulo

The Healthcare Perspective in South America

read more »
PlaySAFEHEART: Consider more than coronary complications in FH

SAFEHEART: Consider more than coronary complications in FH

The Spanish Familial Hypercholesterolaemia Cohort Study (SAFEHEART) has highlighted the prevalence and different distribution of atherosclerotic cardiovascular disease (ASCVD) in individuals with familial hypercholesterolaemia (FH, inherited high cholesterol). In particular, coronary artery disease and peripheral artery disease were more prevalent among those with FH than…

read more »
Why do we need a definition for severe forms of familial hypercholesterolemia?

Why do we need a definition for severe forms of familial hypercholesterolemia?

Raul D. Santos MD, PhD on behalf of the International Atherosclerosis Society Panel on Severe Familial Hypercholesterolemia, discusses why this is critical to the best current use of PCSK9 inhibitors in clinical practice. Familial hypercholesterolemia (FH, inherited high cholesterol) is common in individuals who suffer…

read more »
PlayEAS Consensus Panel on Paediatric FH

EAS Consensus Panel on Paediatric FH

Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Spanish Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Portuguese

read more »
PlayODYSSEY FH and patient unmet needs

ODYSSEY FH and patient unmet needs

Less than 1% of people with familial hypercholesterolaemia (FH), the commonest genetic disorder in the world are diagnosed. As FH patients have significantly elevated levels of low-density lipoprotein cholesterol (LDL-C) their consequent risk of cardiovascular death is greatly increased. Therefore, the results of the ODYSSEY…

read more »
Missing FH: How can we improve FH referral and diagnosis?

Missing FH: How can we improve FH referral and diagnosis?

Heterozygous familial hypercholesterolemia (FH) is neither a rare disease nor a sentence to a life full of complications and early death. Recent evidence shows that even when founder effects are taken into account, heterozygous FH affects around 1/200-300 people instead of the historical estimate of…

read more »
PlayImproving the management of the FH patient

Improving the management of the FH patient

Professor Raul Santos from Brazil says that the new therapies which inhibit PCSK9 to significantly reduce low density Lipoprotein Cholesterol (LDL-C) when given in addition to other cholesterol lowering drugs offer a very important advance in reducing cardiovascular risk in people with Familial Hypercholesterolemia (FH).

read more »